Skip to main content
Back to RA Capital Management

RA Capital Management's Genetics Portfolio

Browse 18 Genetics companies funded by RA Capital Management. See funding amounts, founder contacts, and investment details.

Genetics Companies
18
Total Funding in Genetics
$1.9B

Genetics Portfolio Companies (18)

Export
BiopharmaBiotechnologyGeneticsHealth CareTherapeutics

Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.

Cambridge, United States
July 2021
$50.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsHealth DiagnosticsLife Science

Element Biosciences develops genomic sequencing and multiomics technologies used in drug discovery, and diagnostic applications.

San Diego, United States
June 2026
Series E

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsLife Science

Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.

Dallas, United States
June 2026
$200.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiotechnologyGenetics

NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17.

Boston, United States
June 2026
$34.0M
Venture - Series Unknown

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsHealth CareMedicalPharmaceuticalTherapeutics

Moderna Therapeutics is a biotechnology company that develops medicines and vaccines based on messenger RNA (mRNA) technology.

Cambridge, United States
June 2026
$50.0M
Grant

Founder Contacts

30,000+ verified contacts

BiopharmaBiotechnologyGeneticsMedical

SonoThera develops ultrasound-based technologies for delivering genetic therapies to targeted tissues.

South San Francisco, United States
June 2026
$125.0M
Series B

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsHealth CareMedical

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

Charlestown, United States
March 2026
$240.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsHealth CareMedicalPharmaceuticalTherapeutics

Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).

Natick, United States
March 2024
$182.0M
Series C

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsHealth CareHealth Diagnostics

Orchard Therapeutics is a biotechnology company dedicated to assisting patients through innovative gene therapies.

London, United Kingdom
March 2023
$34.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsHealth DiagnosticsOncologyPharmaceutical

Genetix Biotherapeutics develops and delivers approved gene therapies for severe rare genetic diseases like sickle cell.

Somerville, United States
February 2025
Private Equity

Founder Contacts

30,000+ verified contacts

Artificial Intelligence (AI)BiotechnologyGeneticsIndustrial AutomationInnovation ManagementLife ScienceMachine LearningSoftware

Synthego is a genome engineering company that enables access to CRISPR to accelerate life science research and development.

Redwood City, United States
February 2022
$200.0M
Series E

Founder Contacts

30,000+ verified contacts

BiopharmaBiotechnologyGeneticsLife Science

Gameto is a biotechnology company developing therapeutics of the female reproductive system using cell engineering.

New York, United States
August 2025
$44.0M
Series C

Founder Contacts

30,000+ verified contacts

GeneticsHealth CareMedical

Sidera Bio harness human genetics, that helps in transformative medicines for patients.

Copenhagen, Denmark
December 2025
$109.0M
Series A

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsMedicalTherapeutics

GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.

South San Francisco, United States
December 2021
$300.0M
Post-IPO Debt

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsLife Science

Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.

Boston, United States
November 2023
$143.8M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiopharmaBiotechnologyGeneticsHealth DiagnosticsTherapeutics

NanoMosaic provides solutions for early illness detection, prognostic monitoring, and biomarker identification.

Waltham, United States
November 2025
$3.0M
Venture - Series Unknown

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsHealth CareLife ScienceTherapeutics

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.

Waltham, United States
October 2025
$40.0M
Series C

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsHealth CareLife Science

AavantiBio is a biopharmaceutical company that provides gene transfer and gene editing therapies to treat genetic diseases.

Cambridge, United States
October 2020
$107.0M
Series A

Founder Contacts

30,000+ verified contacts

Explore RA Capital Management's Full Portfolio

View all companies funded by RA Capital Management across every industry and funding stage.

View Full RA Capital Management Portfolio